('Synairgen' or the 'Company')
Synairgen Presented Phase 2 Sub-group Analysis for SNG001 in COVID-19 at the European Congress of Clinical Microbiology & Infectious Diseases
Southampton, UK - 25 April 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, presented the sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held in Lisbon, Portugal from 23-26 April 2022.
The positive results of this Phase 2 study (SG016) in the hospital setting were first announced in July 2020 and published in The Lancet Respiratory Medicine in November 2020.
Title: Effects of Inhaled interferon beta on hospitalised COVID-19 patients receiving supplemental oxygen
Abstract Number: 02567
Session type: 1-Hour Mini-oral Flash Session
Session name: COVID-19 treatment insights and advances
Session date and time: 23 April 2022 at 11:00 WEST
The poster presentation is now available on the Synairgen website. For further information on ECCMID visit: https://www.eccmid.org/
Further analysis of the SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco.
For further enquiries, please contact:
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Namrata Taak
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Tel: +1 516-606-6545
Notes for Editors
About the Phase 2 study (SG016, NCT04385095)
SG016 was a double-blind, placebo-controlled trial. The 220-patient trial comprised c. 100 patients initiated in hospital and 120 patients initiated in the home setting. The patients that participated in the hospital setting, which completed recruitment in May 2020, were recruited across a number of NHS trusts and the trial had been adopted by the NIHR Respiratory Translational Research Collaboration which is comprised of leading centres in respiratory medicine in the UK whose internationally recognised experts are working together to accelerate development and discovery for COVID-19.
SNG001 is a pH-neutral formulation of interferon-beta (IFN-beta) for inhalation that is delivered directly into the lungs using a mesh nebuliser, currently being investigated as a potential host-directed antiviral treatment for COVID-19 patients.
The SARS-CoV-2 virus has been shown to suppress the production of IFN-beta, a naturally occurring protein that orchestrates the body's antiviral defences, with the aim of evading host immune responses. By administering IFN-beta into the lungs, the aim is to correct this deficiency, potentially switching back on the lungs' antiviral pathways to clear the virus. SNG001 has been shown to demonstrate potent in vitro antiviral activity against a broad range of viruses including COVID-19 and Alpha, Beta, Gamma, Delta and Omicron variants.
Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). The topline data from Synairgen's Phase 3 clinical programme evaluating SNG001 in patients across 17 countries was announced in February 2022 and detailed analysis of the data is ongoing.
Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.